{"id":3421,"date":"2018-06-21T00:00:00","date_gmt":"2021-03-19T01:24:34","guid":{"rendered":"https:\/\/www.eisai.com.cn\/?p=3421"},"modified":"2021-03-19T11:37:14","modified_gmt":"2021-03-19T03:37:14","slug":"abbvie-and-eisai-announce-the-launch-of-humira-for-subcutaneous-injection-20-mg-syringe-0-2-ml-a-new-pediatric-formulation-of-humira","status":"publish","type":"post","link":"https:\/\/www.eisai.com.cn\/en\/2018\/06\/21\/abbvie-and-eisai-announce-the-launch-of-humira-for-subcutaneous-injection-20-mg-syringe-0-2-ml-a-new-pediatric-formulation-of-humira\/","title":{"rendered":"AbbVie and Eisai Announce the Launch of HUMIRA\u00ae for Subcutaneous Injection 20 mg Syringe 0.2 mL, A New Pediatric Formulation of HUMIRA\u00ae"},"content":{"rendered":"<p class=\"a\">TOKYO, June 21, 2018 \u2013 AbbVie GK (Headquarters: Tokyo, President: James Feliciano, \u201cAbbVie\u201d) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) announced that HUMIRA<sup>\u00ae<\/sup>\u00a0for Subcutaneous Injection 20 mg Syringe 0.2 mL, a new pediatric formulation of HUMIRA\u00a0<sup>\u00ae<\/sup>\u00a0(generic name: adalimumab [recombinant], \u201cHUMIRA\u201d), a fully human anti-TNF-\u03b1 monoclonal antibody formulation, has been launched today after being listed in the National Health Insurance reimbursement price list on June 15.<\/p>\n<p class=\"a\">HUMIRA has an indication of \u201ctreatment of polyarticular juvenile idiopathic arthritis (JIA)\u201d that develops in pediatric patients.<br \/>\nHUMIRA<sup>\u00ae<\/sup>\u00a0for Subcutaneous Injection 20 mg Syringe 0.2 mL is a higher-concentration formulation, which is produced by removing some excipients, and has the same active ingredient as that of, HUMIRA<sup>\u00ae<\/sup>\u00a0for Subcutaneous Injection 20 mg Syringe 0.4 mL that has been commercially available since September 2011. It has also the same formulation and concentration as those of HUMIRA<sup>\u00ae<\/sup>\u00a0for Subcutaneous Injection 40 mg Syringe 0.4 mL and HUMIRA<sup>\u00ae<\/sup>\u00a0for Subcutaneous Injection 80 mg Syringe 0.8 mL that were launched in November 2016. Outside of Japan, two phase 2, randomized, single- blind, two-period crossover studies were conducted with HUMIRA<sup>\u00ae<\/sup>\u00a0for Subcutaneous Injection 40 mg Syringe 0.4 mL, to compare injected site-related pain between this higher-concentration formulation and the former formulation, using a visual analog scale (VAS). Patients with rheumatoid arthritis showed a significantly lower VAS pain score after injection of the higher-concentration formulation, as compared with the former formulation.<\/p>\n<p class=\"a\">JIA is an autoimmune disease that generally affects children under 16 years of age and is an umbrella term used to define a group of conditions occurring among children that include some form of chronic arthritis. In Japan, JIA affects 10-15 persons per 100,000 children, and is designated as an incurable disease by the Ministry of Health, Labour and Welfare. Polyarticular JIA is a type of JIA which involves five or more joints. Symptoms include painful and swollen joints, limping, morning stiffness, decreased activity and the reluctance to use an arm or leg.<\/p>\n<p class=\"a\">AbbVie and Eisai will continue to promote and provide information on the proper use of HUMIRA\u00ae while making further contributions to improve the quality of life of patients including children.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>TOKYO, June 21, 2018 \u2013 AbbVie GK (Headquarters: Tokyo, President: James Feliciano, \u201cAbbVie\u201d) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) announced that HUMIRA\u00ae\u00a0for Subcutaneous Injection 20 mg Syringe 0.2 mL, a new pediatric formulation of HUMIRA\u00a0\u00ae\u00a0(generic name: adalimumab [recombinant], \u201cHUMIRA\u201d), a fully human anti-TNF-\u03b1 monoclonal antibody formulation, has been launched today after being listed in the National Health Insurance reimbursement price list on June 15.<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28],"tags":[],"class_list":["post-3421","post","type-post","status-publish","format-standard","hentry","category-news-en"],"_links":{"self":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/3421"}],"collection":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/comments?post=3421"}],"version-history":[{"count":1,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/3421\/revisions"}],"predecessor-version":[{"id":3422,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/3421\/revisions\/3422"}],"wp:attachment":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/media?parent=3421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/categories?post=3421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/tags?post=3421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}